Changes in brain functional network efficiency assessed by resting state fMRI
long-term secondary outcome
Changes in brain functional network activity intensity assessed by resting state fMRI
long-term secondary outcome
Changes in brain functional network efficiency assessed by resting state fMRI
long-term secondary outcome
Changes in brain functional network activity intensity assessed by resting state fMRI
long-term secondary outcome
Changes in brain functional network efficiency assessed by resting state fMRI
short-term secondary outcome
Changes in brain functional network activity intensity assessed by resting state fMRI
short-term secondary outcome
Changes in brain functional network connectivity assessed by resting state fMRI
long-term secondary outcome
Changes in brain functional network connectivity assessed by resting state fMRI
long-term secondary outcome
Global cognitive function change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
short-term secondary outcome
Global cognitive function change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
long-term secondary outcome
Global cognitive function change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
long-term secondary outcome
Cognitive domain change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
short-term secondary outcome
Cognitive domain change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
long-term secondary outcome
Cognitive domain change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
long-term secondary outcome
Cognitive function change assessed with Mini-Mental State Examination (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
short-term secondary outcome
Cognitive function change assessed with Mini-Mental State Examination (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
long-term secondary outcome
Cognitive function change assessed with Mini-Mental State Examination (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
long-term secondary outcome
Cognitive function change assessed by Montreal Cognitive Assessment (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
short-term secondary outcome
Cognitive function change assessed by Montreal Cognitive Assessment (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
long-term secondary outcome
Cognitive function change assessed by Montreal Cognitive Assessment (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
long-term secondary outcome
Changes in white matter hyperintensity (WMH) assessed on MRI with T2-Fluid-Attenuated-Inversion-Recovery (FLAIR) sequence
short-term secondary outcome
Changes in lacunes assessed on MRI with T2 FLAIR sequence
short-term secondary outcome
Changes in perivascular spaces assessed on MRI with T2 FLAIR sequence
short-term secondary outcome
Changes in microbleeds assessed on MRI with Susceptibility Weighted Imaging (SWI) sequence sequence
short-term secondary outcome
Changes in brain atrophy (width of the sulci greater than 5mm) assessed on MRI
short-term secondary outcome
Changes in white matter hyperintensity (WMH) assessed on MRI with T2 FLAIR sequence
long-term secondary outcome
Changes in white matter hyperintensity (WMH) assessed on MRI with T2 FLAIR sequence
long-term secondary outcome
Changes in lacunes assessed on MRI with T2 FLAIR sequence
long-term secondary outcome
Changes in lacunes assessed on MRI with T2 FLAIR sequence
long-term secondary outcome
Changes in perivascular spaces assessed on MRI with T2 FLAIR sequence
long-term secondary outcome
Changes in perivascular spaces assessed on MRI with T2 FLAIR sequence
long-term secondary outcome
Changes in microbleeds assessed on MRI with SWI sequence sequence
long-term secondary outcome
Changes in microbleeds assessed on MRI with SWI sequence sequence
long-term secondary outcome
Changes in brain atrophy (width of the sulci greater than 5mm) assessed on MRI
long-term secondary outcome
Changes in brain atrophy (width of the sulci greater than 5mm) assessed on MRI
long-term secondary outcome
Changes in cerebral glymphatic function assessed by non-invasive diffusion tensor image analysis along the perivascular space (ALPS-index)
short-term secondary outcome
Changes in cerebral glymphatic function assessed by non-invasive diffusion tensor image analysis along the perivascular space (ALPS-index)
long-term secondary outcome
Changes in cerebral glymphatic function assessed by non-invasive diffusion tensor image analysis along the perivascular space (ALPS-index)
long-term secondary outcome
Changes in cerebral blood flow (CBF) in the territory of the culprit artery assessed by arterial spin labeling (ASL) perfusion image
short-term secondary outcome
Changes in cerebral blood flow (CBF) in the territory of the culprit artery assessed by arterial spin labeling (ASL) perfusion image
long-term secondary outcome
Changes in cerebral blood flow (CBF) in the territory of the culprit artery assessed by arterial spin labeling (ASL) perfusion image
long-term secondary outcome
Metabolite profiles in participants' faecal samples and serum samples
short-term secondary outcome: metabolite composition was analyzed via liquid chromatography tandem mass spectrometry (LC-MS/MS)
Metabolite profiles in participants' faecal samples and serum samples
long-term secondary outcome: metabolite composition was analyzed via liquid chromatography tandem mass spectrometry (LC-MS/MS)
Incidence of stroke event including ischemic and hemorrhagic stroke
short-term secondary outcome
Incidence of stroke event including ischemic and hemorrhagic stroke
long-term secondary outcome
Incidence of stroke event including ischemic and hemorrhagic stroke
long-term secondary outcome
Change in the Oriental Intervention for Enhanced Neurocognitive Health (ORIENT) diet scale (minimum value = 0, maximum value = 14, and higher scores mean a better outcome)
short-term secondary outcome
Change in the Mediterranean-DASH Diet Intervention for Neurodegenerative Delay (MIND) diet scale (minimum value = 0, maximum value = 15, and higher scores mean a better outcome)
short-term secondary outcome